TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36510486

Group type: EXPERIMENTAL
Intervention: Budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) 320/14.4/10 µg
Number of subjects: 8509

Group type: EXPERIMENTAL
Intervention: Budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) 160/14.4/10 µg
Number of subjects: 8509

Group type: COMPARATOR
Intervention: Glycopyrronium/formoterol fumarate dihydrate (GFF) 14.4/10 µg
Number of subjects: 8509

Group type: COMPARATOR
Intervention: Budesonide/formoterol fumarate dihydrate (BFF) 320/10 µg
Number of subjects: 8509
Study: 36510662

Group type: EXPERIMENTAL
Intervention: Neutralization of ACBP/DBI through a monoclonal antibody
Number of subjects: 0

Group type: COMPARATOR
Intervention: High ACBP/DBI levels
Number of subjects: 0
Study: 36510778

Group type: EXPERIMENTAL
Intervention: Mixed carcinoma (10.9% of patients, n=787)
Number of subjects: 7215

Group type: EXPERIMENTAL
Intervention: Mixed carcinoma
Number of subjects: 7215
Study: 36510826

Group type: EXPERIMENTAL
Intervention: Usual care plus intervention group 1 (IG-1)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Usual care plus intervention group 2 (IG-2)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual care only (control group, CG)
Number of subjects: 57
Study: 36511149

Group type: EXPERIMENTAL
Intervention: Elevated plasma osteoprotegerin levels
Number of subjects: 3490

Group type: EXPERIMENTAL
Intervention: Each 1-SD higher log-osteoprotegerin
Number of subjects: 3490
Study: 36511181

Group type: EXPERIMENTAL
Intervention: Oral trimethoprim and sulfamethoxazole combined with rifampicin (administered for 2 weeks with decontamination or for 21 days with intranasal mupirocin)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Oral trimethoprim and sulfamethoxazole combined with rifampicin
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Nebulised vancomycin with oral antibiotics
Number of subjects: 135
Study: 36511191

Group type: EXPERIMENTAL
Intervention: Original adalimumab product for 24 weeks followed by BI 695501 for 22 weeks
Number of subjects: 2

Group type: COMPARATOR
Intervention: BI 695501 for the entire 46-week treatment period
Number of subjects: 2
Study: 36511389

Group type: EXPERIMENTAL
Intervention: Immediate switch to tenofovir alafenamide (TAF)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Delayed switch to tenofovir alafenamide (TAF) after 48 weeks
Number of subjects: 34
Study: 36511784

Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 652

Group type: COMPARATOR
Intervention: Ibrutinib
Number of subjects: 652
Study: 36511804

Group type: EXPERIMENTAL
Intervention: Cancer with a Gleason score of 3+4
Number of subjects: 161

Group type: COMPARATOR
Intervention: Negative TPM results
Number of subjects: 161
Study: 36511831

Group type: EXPERIMENTAL
Intervention: MiniMed 780G™
Number of subjects: 0
Study: 36511871

Group type: EXPERIMENTAL
Intervention: Composite Metric of Glycemic Control Q-Score
Number of subjects: 0
Study: 36511925

Group type: EXPERIMENTAL
Intervention: Diet and exercise intervention (n=414)
Number of subjects: 823

Group type: COMPARATOR
Intervention: Attention control (n=409)
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Diet and exercise intervention (n=289)
Number of subjects: 823

Group type: COMPARATOR
Intervention: Attention control (n=273)
Number of subjects: 823
Study: 36511926

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Combined MBSR and exercise
Number of subjects: 585

Group type: COMPARATOR
Intervention: Health education control group
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Secondary outcomes (hippocampal volume, dorsolateral prefrontal cortex thickness and surface area, functional cognitive capacity, self-reported cognitive concerns)
Number of subjects: 585
Study: 36511927

Group type: EXPERIMENTAL
Intervention: Self-directed, remotely administered behavioral lifestyle intervention (Diabetes Prevention Program-based videos, handouts, coaching messages) for 12 months
Number of subjects: 511

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Self-directed, remotely administered behavioral lifestyle intervention
Number of subjects: 511
Study: 36512069

Group type: EXPERIMENTAL
Intervention: Sivopixant 50 mg
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Sivopixant 150 mg
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Sivopixant 300 mg
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study: 36512093

Group type: EXPERIMENTAL
Intervention: ePRO pathway (electronic patient-reported outcome questionnaire, blood test, and telephone consultation with a specialist nurse)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ePRO pathway
Number of subjects: 24
Study: 36512175

Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg once daily
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg once daily
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Abrocitinib (both doses)
Number of subjects: 837

Group type: COMPARATOR
Intervention: Dupilumab
Number of subjects: 837

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 837
Study: 36512254

Group type: EXPERIMENTAL
Intervention: Newly diagnosed DLB patients
Number of subjects: 116
Study: 36512271

Group type: EXPERIMENTAL
Intervention: Shoulder-Café intervention
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 109
Study: 36512301

Group type: EXPERIMENTAL
Intervention: Salivary gland cancer (SGC) patients
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Salivary gland cancer (SGC) patients diagnosed at stages I and IV
Number of subjects: 225
Study: 36512619

Group type: EXPERIMENTAL
Intervention: Evocalcet low dose (1-2 mg)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Evocalcet medium dose (3-4 mg)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Evocalcet high dose (5-8 mg)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Evocalcet (all doses)
Number of subjects: 313
Study: 36512631

Group type: EXPERIMENTAL
Intervention: Healthy Options intervention (EUDC + PST + CBT sessions)
Number of subjects: 742

Group type: COMPARATOR
Intervention: Enhanced usual care for depression (EUDC)
Number of subjects: 742
Study: 36512649

Group type: EXPERIMENTAL
Intervention: 68 Ga-PSMA-11 PET/CT
Number of subjects: 8
Study: 36512671

Group type: EXPERIMENTAL
Intervention: ABBV-3373 (100 mg IV every other week for 12 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: adalimumab (80 mg every other week for 24 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: combined in-trial/historical adalimumab
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: ABBV-3373
Number of subjects: 48
Study: 36512738

Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg once every 2 weeks plus cabozantinib 40 mg once daily (doublet arm)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks plus cabozantinib 40 mg once daily with ipilimumab 1 mg/kg once every 6 weeks (triplet arm)
Number of subjects: 71
Study: 36513051

Group type: EXPERIMENTAL
Intervention: On-label reduced-dose edoxaban
Number of subjects: 2448
Study: 36513186

Group type: EXPERIMENTAL
Intervention: ARO-HSD 25 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: ARO-HSD 100 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: ARO-HSD 200 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: ARO-HSD pooled cohorts
Number of subjects: 18
Study: 36513449

Group type: EXPERIMENTAL
Intervention: Soy isoflavones (136.6 mg as aglycone equivalents)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 36513490

Group type: EXPERIMENTAL
Intervention: Porcine protein supplement (twice a day for 6 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Maltodextrin supplement (twice a day for 6 weeks)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 72
Study: 36513620

Group type: EXPERIMENTAL
Intervention: Hypnofertility-based relaxation, visualisation, imagination, and affirmation techniques
Number of subjects: 0
Study: 36513665

Group type: EXPERIMENTAL
Intervention: mRNA1273
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: BNT162b2
Number of subjects: 700
Study: 36513815

Group type: EXPERIMENTAL
Intervention: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with Cisplatin (7.5 mg/m2)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
Number of subjects: 108
Study: 36513852

Group type: EXPERIMENTAL
Intervention: Persistent diaphragm dysfunction (8% incidence)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Persistent diaphragm dysfunction
Number of subjects: 122
Study: 36513895

Group type: EXPERIMENTAL
Intervention: Ostomy Self-Management Training (OSMT) program delivered by telehealth over 5 weeks
Number of subjects: 167

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 167
Study: 36513991

Group type: EXPERIMENTAL
Intervention: Immunotherapy (anti-PD1/PDL1 or anti-CTLA4 monotherapy or combination therapy)
Number of subjects: 100
Study: 36514017

Group type: EXPERIMENTAL
Intervention: Conventional irrigation only
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sonic irrigation activation system (EDDY)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Conventional irrigation followed by 980-nm diode laser irradiation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sonic irrigation activation system followed by 980-nm diode laser irradiation
Number of subjects: 80
Study: 36514020

Group type: EXPERIMENTAL
Intervention: Mobile App for smoking cessation with gamification strategy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual clinical practice intervention for smoking cessation
Number of subjects: 200
Study: 36514019

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600 mg tablets taken three times a day)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 36514034

Group type: EXPERIMENTAL
Intervention: Ripretinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36514058

Group type: EXPERIMENTAL
Intervention: Formula with pre- and/or probiotics (FFI_PP)
Number of subjects: 2036

Group type: EXPERIMENTAL
Intervention: Formula without pre- and/or probiotics (FFI_noPP)
Number of subjects: 2036

Group type: COMPARATOR
Intervention: Breastfed infants (BFI)
Number of subjects: 2036

Group type: COMPARATOR
Intervention: Formula-fed infants (FFI)
Number of subjects: 2036
Study: 36514060

Group type: EXPERIMENTAL
Intervention: TAS-102 (trifluridine and tipiracil) and radioembolization (TARE)
Number of subjects: 21
Study: 36514077

Group type: EXPERIMENTAL
Intervention: Pneumatic tourniquet
Number of subjects: 124

Group type: COMPARATOR
Intervention: No tourniquet
Number of subjects: 124
Study: 36514082

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (8-week program)
Number of subjects: 0
Study: 36514099

Group type: EXPERIMENTAL
Intervention: D-Foot digital tool
Number of subjects: 90
Study: 36514106

Group type: EXPERIMENTAL
Intervention: Cord blood red blood cell transfusions (CB-RBCs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard red blood cell transfusions (adult-RBCs)
Number of subjects: 0
Study: 36514143

Group type: EXPERIMENTAL
Intervention: Intravenous nafamostat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Variable dose anticoagulation
Number of subjects: 0
Study: 36514195

Group type: EXPERIMENTAL
Intervention: Prediction model based on continuous glucose monitoring (CGM) data
Number of subjects: 67
Study: 36514197

Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with AYAs with LFS
Number of subjects: 30
Study: 36514248

Group type: EXPERIMENTAL
Intervention: Benzodiazepine and Z-drugs (BZDRs) use
Number of subjects: 4837

Group type: COMPARATOR
Intervention: BZDRs use on an as-needed basis
Number of subjects: 4837

Group type: EXPERIMENTAL
Intervention: BZDRs daily use with increasing doses
Number of subjects: 4837
Study: 36514294

Group type: EXPERIMENTAL
Intervention: Parent Management Training and behavioral sleep intervention
Number of subjects: 22
Study: 36514397

Group type: EXPERIMENTAL
Intervention: Maintenance hemodialysis (HD)
Number of subjects: 66
Study: 36514730

Group type: EXPERIMENTAL
Intervention: Integrated palliative care visits (monthly for 3 months)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual nephrology care
Number of subjects: 45
Study: 36514847

Group type: EXPERIMENTAL
Intervention: Faster-acting aspart
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin aspart
Number of subjects: 0
Study: 36514850

Group type: EXPERIMENTAL
Intervention: Risankizumab 75 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Risankizumab (both doses)
Number of subjects: 17
Study: 36514996

Group type: EXPERIMENTAL
Intervention: Baricitinib 4-mg ITT cohort
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Baricitinib 4-mg RPR cohort
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Baricitinib 2-mg RPR cohort
Number of subjects: 102
Study: 36515211

Group type: EXPERIMENTAL
Intervention: Comedy movie intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meditation music intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (routine practices)
Number of subjects: 0
Study: 36515248

Group type: EXPERIMENTAL
Intervention: Persistent depressive symptoms
Number of subjects: 4130

Group type: EXPERIMENTAL
Intervention: New-onset depressive symptoms
Number of subjects: 4130

Group type: EXPERIMENTAL
Intervention: Remitted depressive symptoms
Number of subjects: 4130

Group type: COMPARATOR
Intervention: No depressive symptoms
Number of subjects: 4130
Study: 36515247

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 4015

Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 4015
Study: 36515484

Group type: EXPERIMENTAL
Intervention: JA-CASS (juvenile arthritis child acceptable symptom state)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: JA-PASS (juvenile arthritis parent acceptable symptom state)
Number of subjects: 239
Study: 36515491

Group type: EXPERIMENTAL
Intervention: Continuous intrathecal infusion of bupivacaine combined with low-dose fentanyl
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 36
Study: 36515544

Group type: EXPERIMENTAL
Intervention: Camostat Mesylate (DWJ1248)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36515663

Group type: EXPERIMENTAL
Intervention: ARRY-371797
Number of subjects: 12
Study: 36515673

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) group
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (routine laparoscopic white-light imaging)
Number of subjects: 66
Study: 36515785

Group type: EXPERIMENTAL
Intervention: Pain severity measured by the McGill Pain Questionnaire
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Cancer-specific distress symptoms measured by the Impact of Events Scale-Revised
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Physical and functional well-being measured by the Functional Assessment of Cancer Therapy-General
Number of subjects: 190
Study: 36515808

Group type: EXPERIMENTAL
Intervention: Lateral pelvic lymph node dissection with total mesorectal excision (TME)
Number of subjects: 49
Study: 36515868

Group type: EXPERIMENTAL
Intervention: Minimally supervised home exercise group (group 1)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Home exercise group (group 2)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Total sample (both groups)
Number of subjects: 75
Study: 36515888

Group type: EXPERIMENTAL
Intervention: Probiotic BC30 with a 20-g dose of a blend of rice and pea protein
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (20-g dose of a blend of rice and pea protein without BC30)
Number of subjects: 30
Study: 36515905

Group type: EXPERIMENTAL
Intervention: Digital prosthetic socket fabricated using digital shape capture with a 3D scanner, CAD, and 3D printing
Number of subjects: 11

Group type: COMPARATOR
Intervention: Traditionally handcasted manually fabricated socket
Number of subjects: 11
Study: 36515906

Group type: EXPERIMENTAL
Intervention: Delayed transtibial amputation
Number of subjects: 1

Group type: COMPARATOR
Intervention: Limb salvage
Number of subjects: 1
Study: 36515976

Group type: EXPERIMENTAL
Intervention: Self-expanding TAVI
Number of subjects: 4762

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 4762

Group type: EXPERIMENTAL
Intervention: Self-expanding TAVI (in patients with smaller annuli, 23 mm diameter or smaller)
Number of subjects: 4762

Group type: COMPARATOR
Intervention: Surgery (in patients with smaller annuli, 23 mm diameter or smaller)
Number of subjects: 4762

Group type: EXPERIMENTAL
Intervention: SVD
Number of subjects: 4762
Study: 36515980

Group type: EXPERIMENTAL
Intervention: OmniGraf monitoring in conjunction with medication-related symptom burden (MRSB) monitoring
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: OmniGraf monitoring
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 2000
Study: 36515984

Group type: EXPERIMENTAL
Intervention: 8-day self-guided intervention (SGI) on stress-coping (Intellect)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 321
Study: 36515992

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring data sharing and JITAIs-On
Number of subjects: 30

Group type: COMPARATOR
Intervention: Continuous glucose monitoring data sharing and JITAIs-Off
Number of subjects: 30
Study: 36516076

Group type: EXPERIMENTAL
Intervention: Chlorthalidone at a daily dose of 12.5 or 25 mg
Number of subjects: 13523

Group type: COMPARATOR
Intervention: Hydrochlorothiazide at a daily dose of 25 or 50 mg
Number of subjects: 13523

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 13523

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 13523
Study: 36516082

Group type: EXPERIMENTAL
Intervention: Initial vaccination cohort (210 patients)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Booster vaccination cohort (117 patients)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Patients receiving B-cell-directed therapy
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Booster vaccinations
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Initial vaccination cohort
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Booster vaccination cohort
Number of subjects: 327
Study: 36516078

Group type: EXPERIMENTAL
Intervention: Ad26-MVA group
Number of subjects: 2801

Group type: EXPERIMENTAL
Intervention: rVSV group
Number of subjects: 2801

Group type: EXPERIMENTAL
Intervention: rVSV-booster group
Number of subjects: 2801

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 2801
Study: 36516090

Group type: EXPERIMENTAL
Intervention: B-VEC
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 36516159

Group type: EXPERIMENTAL
Intervention: Agricultural livelihood and finance intervention including training and microfinance loan for purchasing farming implements.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 54
Study: 36516343

Group type: EXPERIMENTAL
Intervention: IV ketamine (0.5-0.75 mg/kg)
Number of subjects: 66
Study: 36516644

Group type: EXPERIMENTAL
Intervention: Mini-BESTest total score in mTBI group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Reactive postural control subdomain in mTBI group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sensory orientation subdomain in mTBI group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dynamic gait subdomain in mTBI group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Anticipatory postural adjustments subdomain in mTBI group
Number of subjects: 90
Study: 36516851

Group type: EXPERIMENTAL
Intervention: Social ballroom dancing
Number of subjects: 25

Group type: COMPARATOR
Intervention: Treadmill walking
Number of subjects: 25
Study: 36517088

Group type: EXPERIMENTAL
Intervention: PVC tracheal tube
Number of subjects: 104

Group type: COMPARATOR
Intervention: WR tracheal tube
Number of subjects: 104
Study: 36517097

Group type: EXPERIMENTAL
Intervention: Breathing exercise (BE) intervention; 4-week self-administered program
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual care and pain information booklet
Number of subjects: 72
Study: 36517099

Group type: EXPERIMENTAL
Intervention: Navigator Programme (Critical Time Intervention case management programme) for 90 days after hospital discharge
Number of subjects: 640

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 640
Study: 36517235

Group type: EXPERIMENTAL
Intervention: Mirogabalin 10 or 15 mg BID for 12 weeks
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Mirogabalin 5 mg BID for 1 week, 10 mg BID for 1 week
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Mirogabalin (various dosages)
Number of subjects: 300
Study: 36517284

Group type: EXPERIMENTAL
Intervention: Ganaxolone, dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36517335

Group type: EXPERIMENTAL
Intervention: 3D transesophageal echocardiogram with live multiplanar reconstruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional 2D transesophageal techniques
Number of subjects: 0
Study: 36517395

Group type: EXPERIMENTAL
Intervention: Cathodic stimulation in the transverse plane
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Caudal cathodic stimulation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oblique stimulation
Number of subjects: 15
Study: 36517469

Group type: EXPERIMENTAL
Intervention: Third dose of BNT162b2
Number of subjects: 0
Study: 36517479

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) to the fornix
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Stimulation of the circuit of Papez and stria terminalis
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Optimal stimulation site at the interface between Papez and stria terminalis
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Modulating specific distributed brain networks related to memory
Number of subjects: 46
Study: 36517740

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) monitoring with two decision-making PCT-based algorithms
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (standard antibiotic therapy without PCT monitoring)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) monitoring
Number of subjects: 107